期刊
NEUROLOGY
卷 78, 期 8, 页码 585-589出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318247fa0e
关键词
-
资金
- American Academy of Neurology
- American Clinical Neurophysiology Society
- Bristol-Myers Squibb
- holds stock in Corticare
- Cyberkinetics Neurotechnology Systems Inc.
- NIH
- NYS SCIRB
- Epilepsy Foundation
- Cadwell Laboratories, Inc.
- Bayer Schering Pharma
- Teva Pharmaceutical Industries Ltd.
- Novartis
- Merck Serono
- Avanir Pharmaceuticals
- Swiss PFO-Consortium
- Neuropathy Association and Nutricia
- Forest Laboratories, Inc.
- Milken Family Foundation
Objective: To evaluate whether spinal cord intraoperative monitoring (IOM) with somatosensory and transcranial electrical motor evoked potentials (EPs) predicts adverse surgical outcomes. Methods: A panel of experts reviewed the results of a comprehensive literature search and identified published studies relevant to the clinical question. These studies were classified according to the evidence-based methodology of the American Academy of Neurology. Objective outcomes of postoperative onset of paraparesis, paraplegia, and quadriplegia were used because no randomized or masked studies were available. Results and Recommendations: Four Class I and 8 Class II studies met inclusion criteria for analysis. The 4 Class I studies and 7 of the 8 Class II studies reached significance in showing that paraparesis, paraplegia, and quadriplegia occurred in the IOM patients with EP changes compared with the IOM group without EP changes. All studies were consistent in showing all occurrences of paraparesis, paraplegia, and quadriplegia in the IOM patients with EP changes, with no occurrences of paraparesis, paraplegia, and quadriplegia in patients without EP changes. In the Class I studies, 16%-40% of the IOM patients with EP changes developed postoperative-onset paraparesis, paraplegia, or quadriplegia. IOM is established as effective to predict an increased risk of the adverse outcomes of paraparesis, paraplegia, and quadriplegia in spinal surgery (4 Class I and 7 Class II studies). Surgeons and other members of the operating team should be alerted to the increased risk of severe adverse neurologic outcomes in patients with important IOM changes (Level A). Neurology (R) 2012;78:585-589
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据